||Recombinant Human HER2 /ErbB2 MS Standard Protein, C13 and N15-labeled (HER2 / ErbB2, Heavy Labeled) Thr 23 - Thr 652 (Accession # AAA75493) was produced in human 293 cells (HEK293).
||Human Epidermal growth factor Receptor 2 (HER2),also called ERBB2, HER-2,HER-2 /neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer,communication at the neuromuscular junction andregulation of cell growth and differentiation .[2-6]
||Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.
||HER2 / ErbB2, Heavy Labeled, fused with 6×His tag at the C-terminus, has a calculated MW of 72.4 kDa. The predicted N-terminus is Thr 23. DTT-reduced Protein migrates as 90-110 kDa due to glycosylation.
||Less than 1.0 EU per μg of the HER2 / ErbB2, Heavy Labeled by the LAL method.
||>95% as determined by SDS-PAGE.
||Avoid repeated freeze-thaw cycles.No activity loss was observed after storage at:In lyophilized state for 1 year (4oC-8oC); After reconstitution under sterile conditions for 1 month (4oC-8oC) or 3 months (-20oC to -70oC).